clavis


Also found in: Encyclopedia, Wikipedia.

clavis

(ˈkleɪvɪs; Latin ˈklɑːwɪs)
n
1. a key
2. a glossary
References in periodicals archive ?
19 August 2010 - Norwegian cancer drug developer Clavis Pharma ASA (OSL: CLAVIS) said Wednesday it has recruited the first patient in its pivotal phase III study assessing its lead product elacytarabine in patients with late-stage acute myeloid leukaemia (AML).
M2 EQUITYBITES-August 19, 2011--DnB NOR sees promising future for Clavis Pharma's candidate elacytarabine(C)2011 M2 COMMUNICATIONS http://www.m2.com
6 August 2010 - Norwegian cancer drug development company Clavis Pharma (OSL: CLAVIS) and its US partner Clovis Oncology Inc said today that the first two patients have been recruited into a Phase II clinical study comparing CP-4126 (also known as CO-1.01) with gemcitabine in the treatment of patients with pancreatic cancer.
NORDIC BUSINESS REPORT-17 June 2010-Investtech rates "buy" on Norwegian Clavis Pharma(C)1994-2010 M2 COMMUNICATIONS http://www.m2.com
30 April 2010 - Norwegian cancer drug development company Clavis Pharma ASA (OSL: CLAVIS) said today that it has inked a licence agreement with Ventana Medical Systems Inc, a wholly owned member of the Roche Group (VTX: ROG), providing Ventana with exclusive access to Clavis Pharma's monoclonal antibody targeting human nucleoside transporter 1 (hENT1) and to the hybridoma cell line that produces the antibody.
23 April 2010 - Norwegian cancer drug developer Clavis Pharma ASA (OSL: CLAVIS) said yesterday its partner for the CP-4126 drug candidate, Clovis Oncology Inc has signed a contract to develop and commercialise the hENT1 companion diagnostic with US firm Ventana Medical Systems.
23 April 2010 - Norwegian cancer drug developer Clavis Pharma said yesterday its partner for the CP-4126 drug candidate, Clovis Oncology Inc, has signed a contract to develop and commercialise the hENT1 companion diagnostic with US firm Ventana Medical Systems.
NORDIC BUSINESS REPORT-17 February 2010-Norwegian Clavis Pharma Q4 '09 net loss narrows to NOK24.3m(C)1994-2010 M2 COMMUNICATIONS http://www.m2.com
M2 EQUITYBITES-May 5, 2011--Norwegian Clavis Pharma after-tax loss expands in Q1 2011(C)2011 M2 COMMUNICATIONS http://www.m2.com
Clavis Pharma (OSL: CLAVIS) got a "buy" rating and a NOK75 target.